Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.




Homo sapiens


Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Doubling time: 48 hours (PubMed=25984343). Microsatellite instability: Stable (MSS) (Sanger). Sequence variation: Homozygous for BAP1 p.Ala95Asp (c.284C>A) (PubMed=21642991; PubMed=26011428). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Genome ancestry: African=0.27%; Native American=0%; East Asian, North=1.66%; East Asian, South=0%; South Asian=0%; European, North=63.32%; European, South=34.76% (PubMed=30894373). DT Created: 04-04-12; Last updated: 05-07-19; Version: 26

Proper Citation

ATCC Cat# CRL-5946, RRID:CVCL_1553


Cancer cell line DT Created: 04-04-12; Last updated: 05-07-19; Version: 26


DT Created: 04-04-12; Last updated: 05-07-19; Version: 26


H2452, H-2452, NCIH2452 DT Created: 04-04-12, Last updated: 05-07-19, Version: 26



Cat Num


Cross References

CLO; CLO_0008077 EFO; EFO_0006680 ArrayExpress; E-MTAB-2706 ArrayExpress; E-MTAB-2770 ArrayExpress; E-MTAB-3610 ATCC; CRL-5946 BioSample; SAMN03471009 BioSamples; SAMEA100910 BioSample; SAMN10988138 CCLE; NCIH2452_PLEURA CCRID; 3131C0001001200017 Cell_Model_Passport; SIDM00722 ChEMBL-Cells; CHEMBL3308580 ChEMBL-Targets; CHEMBL1075540 Cosmic; 886392 Cosmic; 908462 Cosmic; 1032373 Cosmic; 1481546 Cosmic; 1522763 Cosmic; 1541212 Cosmic; 1571798 Cosmic; 1749557 Cosmic; 1963328 Cosmic; 1995571 Cosmic; 2474096 Cosmic-CLP; 908462 DepMap; ACH-000092 GDSC; 908462 GEO; GSM726266 GEO; GSM827515 GEO; GSM850285 GEO; GSM887424 GEO; GSM888503 GEO; GSM1670234 LiGeA; CCLE_468 LINCS_LDP; LCL-1230 Wikidata; Q54907975 DT Created: 04-04-12; Last updated: 05-07-19; Version: 26


DT Created: 04-04-12; Last updated: 05-07-19; Version: 26

Originate from Same Individual

DT Created: 04-04-12; Last updated: 05-07-19; Version: 26

Publications that use this research resource

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

  • Kolluri KK
  • Elife
  • 2018 Jan 18

Literature context:


Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal. Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). This association is observed across human early passage MM cultures, mouse xenografts and human tumour explants. We demonstrate that BAP1 deubiquitinase activity and its association with ASXL1 to form the Polycomb repressive deubiquitinase complex (PR-DUB) impacts TRAIL sensitivity implicating transcriptional modulation as an underlying mechanism. Death receptor agonists are well-tolerated anti-cancer agents demonstrating limited therapeutic benefit in trials without a targeting biomarker. We identify BAP1 loss-of-function mutations, which are frequent in MM, as a potential genomic stratification tool for TRAIL sensitivity with immediate and actionable therapeutic implications.

Funding information:
  • Cancer Research UK - A17341()
  • NINDS NIH HHS - R01NS043915(United States)
  • Wellcome - WT097452MA()
  • Wellcome Trust - 106555/Z/14/Z()
  • Wellcome Trust - WT107963AIA()